Premium
Thrombin inhibition during PCI in heart failure patients
Author(s) -
Bader Yusuf,
Kimmelstiel Carey
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26438
Subject(s) - bivalirudin , medicine , conventional pci , heparin , randomized controlled trial , cardiology , anticoagulant , heart failure , myocardial infarction
Key Points In this retrospective analysis, CHF patients undergoing PCI had a decrease in mortality, bleeding, and transfusion as well as decreased length of stay and hospital cost when bivalirudin was used when compared to heparin. This study suggests bivalirudin may be the preferred anticoagulant for patients with CHF undergoing PCI. Confirmation of these data might entail analysis of patient‐level, pooled data from randomized controlled trials comparing bivalirudin to heparin in PCI patients with pre‐existing CHF.